admin – Page 8065 – Get News Story

“An Outdoorsman’s Legacy” – Unveiling the Depths of Blake Alma’s Journey

“An Outdoorsman’s Legacy,” by Blake Alma, releases on Jan 1, 2024. This sequel to “An Outdoorsman’s Heart” offers a personal, emotional journey through letters, exploring love, loss, and resilience. Alma, CoinHub founder, shares his growth and connection to nature, creating a universally relatable narrative.

On January 1, 2024, readers around the world will be treated to “An Outdoorsman’s Legacy,” the emotionally charged and deeply personal sequel to “An Outdoorsman’s Heart.” Authored by Blake Alma, founder of CoinHub, this book is a testament to a journey that intertwines the beauty of the natural world with the intricacies of human emotion and growth.

Blake Alma, renowned for his love for the outdoors and his entrepreneurial spirit in founding CoinHub – a company dedicated to coin collecting – now brings his unique perspective to the literary world once again. While CoinHub stands as a symbol of Alma’s diverse interests and expertise, “An Outdoorsman’s Legacy” represents another facet of his passion: storytelling that touches the soul.

In this sequel, Alma shares a collection of letters written over five transformative years. These letters, brimming with sincerity and introspection, delve into themes of love, loss, faith, and resilience. Through this intimate form of expression, Alma invites readers to journey with him through the highs and lows of life, offering a mirror to their own experiences and emotions.

“An Outdoorsman’s Legacy” is not just a book; it’s a mosaic of human experiences. As Alma navigates through the challenges and triumphs of his life, he weaves a narrative that is both uniquely personal and universally relatable. His journey is one marked by introspection, growth, and an unyielding connection to the natural world.

This book is a must-read for those who appreciate heartfelt storytelling and seek inspiration in the resilience of the human spirit. It is a reflection of Alma’s journey as an outdoorsman, a writer, and the founder of CoinHub, showcasing his multifaceted life and the lessons learned along the way.

Available for purchase at major book retailers, “An Outdoorsman’s Legacy” is an invitation to explore the depth of human experience, seen through the eyes of someone who has embraced every aspect of life with passion and authenticity.

About the Author:

Blake Alma, the founder of CoinHub and an award-winning writer, brings a unique blend of passion for the outdoors, deep spiritual insight, and entrepreneurial acumen to his latest literary work. His journey from a young, enthusiastic writer to a seasoned author and entrepreneur is not just inspiring; it’s a compelling story of perseverance, faith, and a deep-seated love for the natural world.

Media Contact
Company Name: CoinHub Media
Email: Send Email
Phone: 513-525-8135
City: Cincinnati
State: Ohio
Country: United States
Website: www.coinhubmedia.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: \”An Outdoorsman\’s Legacy\” – Unveiling the Depths of Blake Alma’s Journey

Dimethylformamide (DMF) Market Set to Flourish with Anticipated Worth of $2.7 Billion by 2027

“Browse 261 market data Tables and 38 Figures spread through 205 Pages and in-depth TOC on “Dimethylformamide (DMF) Market””

Dimethylformamide (DMF) Market by Type (Reactant and Feedstock), End-use industries (Chemicals, Electronics, Pharmaceutical, and Agrochemical), and Region (Asia Pacific, Europe, North America, Europe, MEA and South America) – Global Forecast to 2027

The Dimethylformamide (DMF) Market is projected to grow from USD 2.3 billion in 2022 to USD 2.7 billion by 2027, at a CAGR of 3.2% between 2022 and 2027. Asia Pacific is estimated to be the largest consumer of DMF. The global DMF market is driven by the growing demand for DMF in different end-use industries.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=129340374

The key players operating in the market are Shandong Hualu Hengsheng (China), Jiutian Chemical Group Limited (Singapore), Luxi Chemical Group Co., Ltd. (China), Shaanxi Xinghua Chemistry (China), and Shandong jinmei Riyue Chemical Co., Ltd. (China).

Jiutian Chemical Group Limited is a specialist in the fine chemical industry. It manufactures and produces DMF, methylamine, sodium hydrosulfite, and Dimethylacetamide (DMAC). It is also involved in the processing and sale of consumable carbon dioxide, oxygen-18, and deuterium-depleted water. It is one of the leading players in the DMF market globally. The company has successfully used available local resources to cater to the local as well as the global market. Also, the Singapore government has increased the investments in infrastructure to facilitate and improve the business environment, which has been accessed by the organization to drive growth.

Shaanxi Xinghua Chemistry Co., Ltd. manufactures and sells chemical products such as ammonium nitrate, porous ammonium nitrate, compounded fertilizers, nitric acid, and carbon-based iron powders. It is a well-established chemical manufacturer in China that accounts for the major share of the DMF market in Asia Pacific. The company has become the largest production base of ammonium nitrate, and its product sales have covered 25 provinces and autonomous regions.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=129340374

According to Statista, the revenue generated by the country’s appliances business is expected to expand at a 9.4% annual pace between 2020 and 2024, reaching USD 70,388 million by 2024. The country’s population’s level of living and spending power are steadily rising, bolstering the appliance business. It encourages the rapid growth of both foreign and Chinese brands. The country’s growing appliance industry is driving up the use of DMF.

Read Our Trending Press Release Below:

Syntactic Foam Market – Global Forecast to 2025

Cosmetic Pigments Market – Global Forecast to 2026

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/dimethylformamide-market-129340374.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dimethylformamide (DMF) Market Set to Flourish with Anticipated Worth of $2.7 Billion by 2027

Personal Cloud Market Growth, Opportunities Business Scenario, Share, Growth Size, Scope, Key Segments and Forecast to 2027

“Alphabet Inc, (US), Microsoft Corporation (US), Apple Inc. (US), Dropbox, Inc. (US), Amazon Web Services, Inc. (US), Box (US), Seagate Technology LLC (US), Western Digital Corporation (US), Synchronoss Technologies, Inc. (US), Egnyte, Inc. (US), Buffalo Inc. and Melco Holdings Inc. (Japan), Funambol, Inc. (US), j2 Global, Inc. (US), and OpenDrive Inc. (US).”

Personal Cloud Market by Revenue Type, User Type (Enterprises (SMEs and Large Enterprises) and Consumers), and Region (North America, Europe, Asia Pacific, Middle East & Africa and Latin America) (2022 – 2027)

The global personal cloud market is projected to grow from USD 20.8 billion in 2022 to USD 50.8 billion by 2027 at a compound annual growth rate (CAGR) of 19.6% during the forecast period. Personal cloud is a cloud storage platform that allows customers to access, synchronize, and share data stored in the cloud and across devices. Personal cloud services provide improved data storage, accessibility, and sharing, as well as enhanced security features. They have raised the bar for individuals to use cloud computing services by providing a better user experience and ease of use. The personal cloud market is gaining popularity across industries as there is a rise in the number of devices, which has increased the demand for high bandwidth applications with the growing use of internet services.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=821

The Consumer segment is estimated to have the largest market size during the forecast period

Since the introduction of the internet, the computer industry has been shifting away from local to server-based storage. However, it was only with the introduction of personal storage and file-sharing services that cloud storage began to achieve popular notice and use. The drive toward the personal cloud is to complete utilization of the storage of computer or mobile as consumers can put media and documents in an online drive and share it across devices.

The SMEs is expected to hold a higher growth rate during the forecast period

Personal cloud is undoubtedly one of the most profitable investments a small firm can make. Due to its cost-effectiveness and flexibility of use, online storage solutions for small businesses have exploded in popularity in recent years. These cloud-based storage systems are scalable and dont require a large upfront investment in physical storage equipment. Other benefits of using Cloud storage solutions include disaster recovery, increased security, and real-time data updates. Some of the key players for SMEs are Spideroak, Just Cloud, which supports third-party apps to run smoothly and efficiently. Cloud storage for SMEs has some features, such as workflow management, data management, and user management. Small business storage and backup options provide 100% data security and privacy, as well as complete customer control.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=821

Unique Features in the Personal Cloud Market

User data could be easily accessed from various platforms by using personal cloud services, which frequently offered interoperability across numerous operating systems (Windows, macOS, Linux, iOS, Android) and devices (computers, smartphones, tablets).

Users were able to automatically backup and synchronise their papers, movies, images, and other types of content. Data consistency was ensured via the synchronisation of changes made on one device with all associated devices.

An emphasis was placed on robust privacy and security features. To protect private information from unwanted access, personal cloud services included secure login options, encryption, and access permission management.

Sharing files, folders, and documents with others was made possible via collaboration features. Cooperative work is facilitated by the availability of collaboration capabilities on personal cloud platforms, such as real-time document editing and commenting.

Media streaming features were often included in personal cloud services, allowing customers to stream photographs, videos, and music straight from their cloud storage, eliminating the need for local storage on devices.

Major Highlights of the Personal Cloud Market

Hybrid cloud solutions, which let users synchronise and integrate data between local storage and cloud-based services, have become more popular in the personal cloud market.

Two of the main concerns in the personal cloud industry were security and privacy. In order to allay user worries over the security of their personal data, providers placed a strong emphasis on data privacy features, secure access controls, and encryption.

By processing data closer to the user’s device, edge computing capabilities were included into personal cloud systems, enabling faster data access and lower latency.

With the evolution of personal cloud services came improved collaboration capabilities that let users exchange files, work together on documents, and complete projects in real time—often by integrating with well-known productivity tools.

In order to improve user experiences, certain personal cloud services combined AI and machine learning, offering functions like intelligent file organisation, content recommendations, and automated tagging.

With the help of personal cloud solutions that let them manage and integrate data across several cloud platforms, users were investigating multi-cloud methods more and more.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=821

Top Key Companies in the Personal Cloud Market

Some of the major players in the personal cloud market are Alphabet Inc, (US), Microsoft Corporation (US), Apple Inc. (US), Dropbox, Inc. (US), Amazon Web Services, Inc. (US), Box(US), Seagate Technology LLC (US), Western Digital Corporation (US), Synchronoss Technologies, Inc. (US), Egnyte, Inc. (US), Buffalo Inc. and Melco Holdings Inc. (Japan), Funambol, Inc. (US), j2 Global, Inc. (US), D-Link Corporation (Taiwan), ElephantDrive Inc. (US), ownCloud(Germany), Cloudike(US), SpiderOak Inc. (US), pCloud AG (Switzerland), Tresorit, and ASUS Cloud Corporation (Switzerland), Internxt Inc. (Spain), IceDrive, Sync.com(Canada), iDrive Inc. (US), MiMedia Inc. (US), Dracoon(Germany), and OpenDrive Inc. (US).

Microsoft is a multinational technology corporation that manufactures computer software, consumer electronics, personal computers, and related services. The Microsoft Windows operating system line, the Microsoft Office suite, and the Internet Explorer and Edge web browsers are among its most well-known software products. The Xbox video game consoles and the Microsoft Surface lineup of touchscreen personal computers are its flagship hardware products. Microsoft has a stake in various verticals, which include Azure, Appsource, automotive, government, healthcare, manufacturing, financial services, and retail.

Apple is a multinational technology company that specializes in consumer electronics, software, and online services. It is the most valuable company in the world, the fourth-largest personal computer vendor in terms of unit sales, and the second-largest mobile phone manufacturer. Along with Alphabet (Google), Amazon, Meta (Facebook), and Microsoft, it is one of the Big Five American information technology companies. Apple has various products, such as Macintosh, iPhone, iPad, wearables, and services. Apple has an intelligent software assistant named Siri, which has cloud synchronized data with iCloud. As cloud storage solutions are becoming increasingly popular, Apple is introducing deep learning scans for facial data in photos on the user’s local device, before uploading the content to Apple’s iCloud storage system.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Personal Cloud Market Growth, Opportunities Business Scenario, Share, Growth Size, Scope, Key Segments and Forecast to 2027

Anticipated Growth in Hand Eczema Market Projected during Forecast Period (2023-2032) by DelveInsight | Companies – Leo Pharma, Asana Biosciences, Regeneron, Sanofi, Incyte

“Hand Eczema Market”

(Albany, USA) DelveInsight’s “Hand Eczema Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hand Eczema, historical and forecasted epidemiology as well as the Hand Eczema market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hand Eczema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hand Eczema Market Forecast

Some of the key facts of the Hand Eczema Market Report:

The Hand Eczema market size was valued approximately USD 11 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
The US experienced the biggest number of Hand eczema instances in 2021—roughly 26,000,000—while Spain experienced the lowest number—roughly 4,000,000
Hand eczema afflicted roughly 11,000,000 men and 16,000,000 women in the United States in 2021, and it is predicted that prevalence will rise and reach up to 11,555,000 men and 16,800,000 women, respectively, by 2032
Germany has the most Hand Eczema cases (more than 7,000,00 cases) among the EU4 and the UK in 2021
Key Hand Eczema Companies: Leo Pharma, Japan Tobacco Inc., Asana Biosciences, Regeneron, Sanofi, Incyte Corporation, ACO Hud Nordic AB, LEO Pharma, LEO Pharma, Arcutis Biotherapeutics, Inc., Acitretin Pharma, and others
Key Hand Eczema Therapies: Delgocitinib, ASN002, Dupilumab, Ruxolitinib cream, Dupilumab, betamethasone valerate, LEO 124249, Delgocitinib, ARQ-252, Acitretin, and others
The Hand Eczema epidemiology based Hand eczema is more prevalent in females as compared to males
The Hand Eczema market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hand Eczema pipeline products will significantly revolutionize the Hand Eczema market dynamics.

Hand Eczema Overview

One of the most typical varieties of eczema and one of the most prevalent skin illnesses globally is hand dermatitis, sometimes referred to as hand eczema. Although it can affect other regions of the hand, it primarily affects the palms. Hand eczema can range in severity from extremely minor to severe, and its course can be either acute or chronic, causing long-term impairment.

Get a Free sample for the Hand Eczema Market Report – https://www.delveinsight.com/report-store/hand-eczema-market

Hand Eczema Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hand Eczema Epidemiology Segmentation:

The Hand Eczema market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Hand Eczema
Prevalent Cases of Hand Eczema by severity
Gender-specific Prevalence of Hand Eczema
Diagnosed Cases of Episodic and Chronic Hand Eczema

Download the report to understand which factors are driving Hand Eczema epidemiology trends @ Hand Eczema Epidemiology Forecast

Hand Eczema Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hand Eczema market or expected to get launched during the study period. The analysis covers Hand Eczema market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hand Eczema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hand Eczema Therapies and Key Companies

Delgocitinib: Leo Pharma/ Japan Tobacco Inc.
ASN002: Asana Biosciences
Dupilumab: Regeneron/Sanofi
Ruxolitinib cream: Incyte Corporation
betamethasone valerate: ACO Hud Nordic AB
LEO 124249: LEO Pharma
Delgocitinib: LEO Pharma
ARQ-252: Arcutis Biotherapeutics, Inc.
Acitretin: Acitretin Pharma

Discover more about therapies set to grab major Hand Eczema market share @ Hand Eczema Treatment Market

Hand Eczema Market Strengths

Widespread prevalence of the disease.
Development of disease-specific treatments and novel therapeutic drug classes such as JAK inhibitors is likely to boost the market growth.

Hand Eczema Market Opportunities

The emerging drugs have a significant opportunity, as there are no disease-specific approved therapies for the treatment of hand eczema in the US
The current management of the disease includes only symptomatic treatments and does not treat the underlying cause of the disease

Scope of the Hand Eczema Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Hand Eczema Companies: Leo Pharma, Japan Tobacco Inc., Asana Biosciences, Regeneron, Sanofi, Incyte Corporation, ACO Hud Nordic AB, LEO Pharma, LEO Pharma, Arcutis Biotherapeutics, Inc., Acitretin Pharma, and others
Key Hand Eczema Therapies: Delgocitinib, ASN002, Dupilumab, Ruxolitinib cream, Dupilumab, betamethasone valerate, LEO 124249, Delgocitinib, ARQ-252, Acitretin, and others
Hand Eczema Therapeutic Assessment: Hand Eczema current marketed and Hand Eczema emerging therapies
Hand Eczema Market Dynamics: Hand Eczema market drivers and Hand Eczema market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Hand Eczema Unmet Needs, KOL’s views, Analyst’s views, Hand Eczema Market Access and Reimbursement

To know more about Hand Eczema companies working in the treatment market, visit @ Hand Eczema Clinical Trials and Therapeutic Assessment

Table of Contents

1. Hand Eczema Market Report Introduction

2. Executive Summary for Hand Eczema

3. SWOT analysis of Hand Eczema

4. Hand Eczema Patient Share (%) Overview at a Glance

5. Hand Eczema Market Overview at a Glance

6. Hand Eczema Disease Background and Overview

7. Hand Eczema Epidemiology and Patient Population

8. Country-Specific Patient Population of Hand Eczema

9. Hand Eczema Current Treatment and Medical Practices

10. Hand Eczema Unmet Needs

11. Hand Eczema Emerging Therapies

12. Hand Eczema Market Outlook

13. Country-Wise Hand Eczema Market Analysis (2019–2032)

14. Hand Eczema Market Access and Reimbursement of Therapies

15. Hand Eczema Market Drivers

16. Hand Eczema Market Barriers

17. Hand Eczema Appendix

18. Hand Eczema Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anticipated Growth in Hand Eczema Market Projected during Forecast Period (2023-2032) by DelveInsight | Companies – Leo Pharma, Asana Biosciences, Regeneron, Sanofi, Incyte

Exploring the Gout Pipeline in 2023: FDA Approvals, Promising Therapies, and Key Players Identified by DelveInsight | TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear & Horizon Therapeutics plc

“Gout Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Gout pipeline constitutes 40+ key companies continuously working towards developing 40+ Gout treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Gout Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Gout Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gout Market.

Some of the key takeaways from the Gout Pipeline Report:

Companies across the globe are diligently working toward developing novel Gout treatment therapies with a considerable amount of success over the years.
Gout companies working in the treatment market are TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics plc, Nippon Chemiphar, Protalix BioTherapeutics, Horizon Therapeutics plc, Arthrosi Therapeutics, Dyve Biosciences, LG Chem, Jiangsu Hengrui Medicine Co., Selecta Biosciences Inc, InventisBio Co., Ltd, Allena Pharmaceuticals, Olatec Therapeutics LLC,Shanton Pharma Co., Ltd., LG Chem, Arthrosi Therapeutics, and others, are developing therapies for the Gout treatment

Emerging Gout therapies in the different phases of clinical trials are- TJC-0434, NC-2700, Research Program, NC-2500, PRX-115, HZN-457, AR-882, DYV700, LC350189, SHR-4640, SEL-212, D-0120 + Allopurinol, ALLN-346, Dapansutrile, SAP001, Tigulixostat, AR882, and others are expected to have a significant impact on the Gout market in the coming years.
In October 2023, ABP-671, a novel oral URAT1 inhibitor, is being tested in a Phase 2b/3 clinical trial for the treatment of chronic gout. Today, the first patient in the trial received their dose. Atom Bioscience, a clinical stage biotechnology company, is developing new treatments for inflammatory and metabolic diseases.
In June 2020, The strategic licensing agreement for the product candidate SEL-212 was signed between Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB. As per the terms of the license agreement, Sobi will oversee the development, regulatory, and commercial operations of SEL-212 in all markets outside of China.
In November 2020, Selecta Biosciences initiated one of two randomized, double-blind, placebo-controlled, parallel arm trials to assess the safety and efficacy of two different SEL-212 dose levels in comparison to placebo.

Gout Overview

Gout is a common form of inflammatory arthritis that is very painful. It usually affects one joint at a time (often the big toejoint). There are times when symptoms get worse, known as flares, and times when there are no symptoms, known as remission.

Get a Free Sample PDF Report to know more about Gout Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/gouty-arthritis-gout-pipeline-insight

Emerging Gout Drugs Under Different Phases of Clinical Development Include:

TJC-0434: TaiwanJ Pharmaceuticals
NC-2700: Nippon Chemiphar
Research Program: HemoShear: Horizon Therapeutics plc
NC-2500: Nippon Chemiphar
PRX-115: Protalix BioTherapeutics
HZN-457: Horizon Therapeutics plc
AR-882: Arthrosi Therapeutics
DYV700: Dyve Biosciences
LC350189: LG Chem
SHR-4640: Jiangsu Hengrui Medicine Co.
SEL-212: Selecta Biosciences Inc
D-0120 + Allopurinol: InventisBio Co., Ltd
ALLN-346: Allena Pharmaceuticals
Dapansutrile: Olatec Therapeutics LLC
SAP001: Shanton Pharma Co., Ltd.
Tigulixostat: LG Chem
AR882: Arthrosi Therapeutics

Gout Route of Administration

Gout pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intravenous
Oral
Parenteral
Subcutaneous
Topical
Molecule Type

Gout Molecule Type

Gout Products have been categorized under various Molecule types, such as

Protein
Small interfering RNA
Small molecule
Product Type

Gout Pipeline Therapeutics Assessment

Gout Assessment by Product Type
Gout By Stage and Product Type
Gout Assessment by Route of Administration
Gout By Stage and Route of Administration
Gout Assessment by Molecule Type
Gout by Stage and Molecule Type

DelveInsight’s Gout Report covers around 40+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Gout product details are provided in the report. Download the Gout pipeline report to learn more about the emerging Gout therapies

Some of the key companies in the Gout Therapeutics Market include:

Key companies developing therapies for Gout are – Jiangsu Hengrui Medicine, Selecta Biosciences, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, Allena Pharmaceuticals, JW Pharmaceutical, Revive Therapeutics, Hinova pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Jiangsu Atom Bioscience and Pharmaceutical, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Nippon Chemiphar, Sinovent, Shenyang Sunshine Pharmaceutical, Rigel Pharmaceuticals, Chongqing Fochon Pharmaceutical, Alnylam Pharmaceuticals, Enzychem Lifesciences, Arrowhead Pharmaceuticals, Horizon Therapeutics, and others.

Gout Pipeline Analysis:

The Gout pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Gout with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gout Treatment.
Gout key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Gout Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gout market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Gout drugs and therapies

Gout Pipeline Market Drivers

The rise in the prevalence of Gout, novel urate-lowering agents are some of the important factors that are fueling the Gout Market.

Gout Pipeline Market Barriers

However, gaps in the quality of care, lack of knowledge about guidelines and evidence based gout management, lack of novel therapies in Gout pipeline and other factors are creating obstacles in the Gout Market growth.

Scope of Gout Pipeline Drug Insight

Coverage: Global
Key Gout Companies: TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics plc, Nippon Chemiphar, Protalix BioTherapeutics, Horizon Therapeutics plc, Arthrosi Therapeutics, Dyve Biosciences, LG Chem, Jiangsu Hengrui Medicine Co., Selecta Biosciences Inc, InventisBio Co., Ltd, Allena Pharmaceuticals, Olatec Therapeutics LLC,Shanton Pharma Co., Ltd., LG Chem, Arthrosi Therapeutics, and others
Key Gout Therapies: TJC-0434, NC-2700, Research Program, NC-2500, PRX-115, HZN-457, AR-882, DYV700, LC350189, SHR-4640, SEL-212, D-0120 + Allopurinol, ALLN-346, Dapansutrile, SAP001, Tigulixostat, AR882, and others
Gout Therapeutic Assessment: Gout current marketed and Gout emerging therapies
Gout Market Dynamics: Gout market drivers and Gout market barriers

Request for Sample PDF Report for Gout Pipeline Assessment and clinical trials

Table of Contents

1. Gout Report Introduction

2. Gout Executive Summary

3. Gout Overview

4. Gout- Analytical Perspective In-depth Commercial Assessment

5. Gout Pipeline Therapeutics

6. Gout Late Stage Products (Phase II/III)

7. Gout Mid Stage Products (Phase II)

8. Gout Early Stage Products (Phase I)

9. Gout Preclinical Stage Products

10. Gout Therapeutics Assessment

11. Gout Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Gout Key Companies

14. Gout Key Products

15. Gout Unmet Needs

16 . Gout Market Drivers and Barriers

17. Gout Future Perspectives and Conclusion

18. Gout Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exploring the Gout Pipeline in 2023: FDA Approvals, Promising Therapies, and Key Players Identified by DelveInsight | TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear & Horizon Therapeutics plc

Latest Updates on Myopia Pipeline Analysis in 2023: Recent FDA, EMA, and PMDA Approvals Explored by Pfizer, ALCON Inc., Bausch Health Companies Inc., Essilor Luxottica, and Johnson & Johnson

“Myopia Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Myopia pipeline constitutes 10+ key companies continuously working towards developing 12+ Myopia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Myopia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Myopia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myopia Market.

Some of the key takeaways from the Myopia Pipeline Report:

Companies across the globe are diligently working toward developing novel Myopia treatment therapies with a considerable amount of success over the years.
Myopia companies working in the treatment market are Santen Pharmaceutical, Sunhawk Vision Biotech, Nevakar, Inc., Cloudbreak Therapeutics, LLC, iVeena Delivery Systems, Sydnexis, Inc., Nevakar, Inc., and others, are developing therapies for the Myopia treatment

Emerging Myopia therapies in the different phases of clinical trials are- STN-1013400, SHJ002, EXP039, CBT-009, IVMED 85, DE 127, SYD-101, NVK-002, and others are expected to have a significant impact on the Myopia market in the coming years.
In October 2023, The PROTECT clinical trial for Visioneering Technologies Inc.’s (VTI) NaturalVue Multifocal 1 Day paediatric myopia progression control contact lenses produced positive interim one-year findings. The findings, which were presented at the American Academy of Optometry Annual Meeting in October 2023, validate the NaturalVue Multifocal 1 Day contact lenses’ effectiveness and safety in slowing the advancement of myopia.
In October 2021, The Food and Drug Administration approved Allergan, an AbbVie subsidiary, to market Vuity (pilocarpine hydrochloric acid ophthalmic solution) 1.25% to treat presbyopia, or age-related hazy near vision, in adults.
In May 2021, The US FDA approved Johnson & Johnson Vision’s ACUVUE Abiliti Overnight Therapeutic Lenses, which are intended to help correct children’s progressive myopia by reshaping the cornea.

Myopia Overview

The most prevalent type of Refractive Error (RE), known as myopia or shortsightedness, causes a person to have clear near vision but poor distance vision. In this case, near refers to the reading distance of 35–40 cm, and far denotes more than three feet. “Rays of light coming from infinity cannot focus in the retina, instead it is focused in front of the retina, when accommodation function is at rest,” is the clinical definition of myopia.

Get a Free Sample PDF Report to know more about Myopia Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/myopia-pipeline-insight

Emerging Myopia Drugs Under Different Phases of Clinical Development Include:

STN-1013400: Santen Pharmaceutical
SHJ002: Sunhawk Vision Biotech
EXP039: Nevakar, Inc.
CBT-009: Cloudbreak Therapeutics, LLC
IVMED 85: iVeena Delivery Systems
DE 127: Santen Pharmaceutical
SYD-101: Sydnexis, Inc.
NVK-002: Nevakar, Inc.

Myopia Route of Administration

Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Myopia Molecule Type

Myopia Products have been categorized under various Molecule types, such as

Oligonucleotide
Peptide
Small molecule

Myopia Pipeline Therapeutics Assessment

Myopia Assessment by Product Type
Myopia By Stage and Product Type
Myopia Assessment by Route of Administration
Myopia By Stage and Route of Administration
Myopia Assessment by Molecule Type
Myopia by Stage and Molecule Type

DelveInsight’s Myopia Report covers around 12+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Myopia product details are provided in the report. Download the Myopia pipeline report to learn more about the emerging Myopia therapies

Some of the key companies in the Myopia Therapeutics Market include:

Key companies developing therapies for Myopia are – ALCON Inc., Bausch Health Companies Inc., Essilor Luxottica (Essilor Ltd), Johnson & Johnson Vision, NIDEK CO. LTD, Topcon Corporation, Zeimer Ophthalmic Systems AG, Carl Zeiss Meditec AG, AbbVie, Sydnexis, Regeneron Pharmaceuticals Inc., Orasis Pharmaceuticals, The Cooper Companies Inc., and others.

Myopia Pipeline Analysis:

The Myopia pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Myopia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myopia Treatment.
Myopia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Myopia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myopia market.

Download Sample PDF Report to know more about Myopia drugs and therapies

Myopia Pipeline Market Drivers

Increase in the prevalence of Myopia, increasing Research and Development activities are some of the important factors that are fueling the Myopia Market.

Myopia Pipeline Market Barriers

However, cost associated with the treatment, unclear pathogenesis of the disease and other factors are creating obstacles in the Myopia Market growth.

Scope of Myopia Pipeline Drug Insight

Coverage: Global
Key Myopia Companies: Santen Pharmaceutical, Sunhawk Vision Biotech, Nevakar, Inc., Cloudbreak Therapeutics, LLC, iVeena Delivery Systems, Santen Pharmaceutical, Sydnexis, Inc., Nevakar, Inc., and others
Key Myopia Therapies: STN-1013400, SHJ002, EXP039, CBT-009, IVMED 85, DE 127, SYD-101, NVK-002, and others
Myopia Therapeutic Assessment: Myopia current marketed and Myopia emerging therapies
Myopia Market Dynamics: Myopia market drivers and Myopia market barriers

Request for Sample PDF Report for Myopia Pipeline Assessment and clinical trials

Table of Contents

1. Myopia Report Introduction

2. Myopia Executive Summary

3. Myopia Overview

4. Myopia- Analytical Perspective In-depth Commercial Assessment

5. Myopia Pipeline Therapeutics

6. Myopia Late Stage Products (Phase II/III)

7. Myopia Mid Stage Products (Phase II)

8. Myopia Early Stage Products (Phase I)

9. Myopia Preclinical Stage Products

10. Myopia Therapeutics Assessment

11. Myopia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Myopia Key Companies

14. Myopia Key Products

15. Myopia Unmet Needs

16 . Myopia Market Drivers and Barriers

17. Myopia Future Perspectives and Conclusion

18. Myopia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Latest Updates on Myopia Pipeline Analysis in 2023: Recent FDA, EMA, and PMDA Approvals Explored by Pfizer, ALCON Inc., Bausch Health Companies Inc., Essilor Luxottica, and Johnson & Johnson

Exploring the Landscape of Acute Kidney Injury Pipeline Drugs 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, & ROA Unveiled by DelveInsight | Atox Bio, AM Pharma Holding, QuarK

“Acute Kidney Injury Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acute Kidney Injury pipeline constitutes 30+ key companies continuously working towards developing 30+ Acute Kidney Injury treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acute Kidney Injury Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Acute Kidney Injury Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Kidney Injury Market.

Some of the key takeaways from the Acute Kidney Injury Pipeline Report:

Companies across the globe are diligently working toward developing novel Acute Kidney Injury treatment therapies with a considerable amount of success over the years.
Acute Kidney Injury companies working in the treatment market are Revelation Biosciences, RegeneRx Biopharmaceuticals, MISSION Therapeutics, Unicycive Therapeutics, Sentien Biotechnologies, Metro International Biotech, Guard Therapeutics AB, Novartis, Angion Biomedica, Vifor Pharma, AM Pharma, Astellas Pharma, Pharming Technologies, RegeneRx Biopharmaceuticals, and others, are developing therapies for the Acute Kidney Injury treatment

Emerging Acute Kidney Injury therapies in the different phases of clinical trials are- REVTx-300, RGN-352, MTX652, UNI-494, SBI-101, MIB-626, RMC-035, TIN816, ANG-3777, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), Timbetasin, and others are expected to have a significant impact on the Acute Kidney Injury market in the coming years.
In October 2022, The FDA in the United States approved Guard Therapeutics’ application for an investigational new drug (IND) for RMC-035 (ROSgard), the firm reported.
In March 2022, A phase two randomised, placebo-controlled, double-blind, adaptive, parallel group clinical trial to assess the effectiveness and safety of RMC-035 in patients at high risk of acute kidney injury after open chest cardiac surgery was started by Guard Therapeutics AB.
In February 2022, Family offices that specialize in investing in biotech led Renibus Therapeutics‘ Series A financing round, which was closed at USD 35 million after the company completed a USD 15 million extension. Renibus’ pipeline, which includes RBT-1, one of the company’s main candidates for the prevention of acute kidney injury, will be advanced with the help of the funding proceeds.
In March 2022, An summary of the ongoing Phase III REVIVAL trial will be presented by AM-Pharma at the 27th International Conference on Advances in Critical Care Nephrology.

Acute Kidney Injury Overview

Acute kidney damage is characterized by a sudden decline in renal function that occurs within a few days to weeks. This can result in azotemia, or a buildup of nitrogenous products in the blood, with or without a drop in urine production.

Get a Free Sample PDF Report to know more about Acute Kidney Injury Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acute-kidney-injury-aki-pipeline-insight

Emerging Acute Kidney Injury Drugs Under Different Phases of Clinical Development Include:

REVTx-300: Revelation Biosciences
RGN-352: RegeneRx Biopharmaceuticals
MTX652: MISSION Therapeutics
UNI-494: Unicycive Therapeutics
SBI-101: Sentien Biotechnologies
MIB-626: Metro International Biotech
RMC-035: Guard Therapeutics AB
TIN816: Novartis Pharmaceuticals
ANG-3777: Angion Biomedica/Vifor Pharma
Ilofotase alfa: AM Pharma
ASP1128: Astellas Pharma
Ruconest (Conestat alfa): Pharming Technologies
Timbetasin: RegeneRx Biopharmaceuticals

Acute Kidney Injury Route of Administration

Acute Kidney Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous

Acute Kidney Injury Molecule Type

Acute Kidney Injury Products have been categorized under various Molecule types, such as

Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine

Acute Kidney Injury Pipeline Therapeutics Assessment

Acute Kidney Injury Assessment by Product Type
Acute Kidney Injury By Stage and Product Type
Acute Kidney Injury Assessment by Route of Administration
Acute Kidney Injury By Stage and Route of Administration
Acute Kidney Injury Assessment by Molecule Type
Acute Kidney Injury by Stage and Molecule Type

DelveInsight’s Acute Kidney Injury Report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Acute Kidney Injury product details are provided in the report. Download the Acute Kidney Injury pipeline report to learn more about the emerging Acute Kidney Injury therapies

Some of the key companies in the Acute Kidney Injury Therapeutics Market include:

Key companies developing therapies for Acute Kidney Injury are – Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma, Kantum Pharma, Nephraegis Therapeutics, Vasomune, Unicycive, ABIONYX and others.

Acute Kidney Injury Pipeline Analysis:

The Acute Kidney Injury pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Acute Kidney Injury with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Kidney Injury Treatment.
Acute Kidney Injury key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Acute Kidney Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Kidney Injury market.

Download Sample PDF Report to know more about Acute Kidney Injury drugs and therapies

Acute Kidney Injury Pipeline Market Drivers

Rising incidence of Acute Kidney injuries, the rising geriatric population are some of the important factors that are fueling the Acute Kidney Injury Market.

Acute Kidney Injury Pipeline Market Barriers

However, side-effects associated with the treatment, lack of awareness and other factors are creating obstacles in the Acute Kidney Injury Market growth.

Scope of Acute Kidney Injury Pipeline Drug Insight

Coverage: Global
Key Acute Kidney Injury Companies: Revelation Biosciences, RegeneRx Biopharmaceuticals, MISSION Therapeutics, Unicycive Therapeutics, Sentien Biotechnologies, Metro International Biotech, Guard Therapeutics AB, Novartis, Angion Biomedica, Vifor Pharma, AM Pharma, Astellas Pharma, Pharming Technologies, RegeneRx Biopharmaceuticals, and others
Key Acute Kidney Injury Therapies: REVTx-300, RGN-352, MTX652, UNI-494, SBI-101, MIB-626, RMC-035, TIN816, ANG-3777, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), Timbetasin, and others
Acute Kidney Injury Therapeutic Assessment: Acute Kidney Injury current marketed and Acute Kidney Injury emerging therapies
Acute Kidney Injury Market Dynamics: Acute Kidney Injury market drivers and Acute Kidney Injury market barriers

Request for Sample PDF Report for Acute Kidney Injury Pipeline Assessment and clinical trials

Table of Contents

1. Acute Kidney Injury Report Introduction

2. Acute Kidney Injury Executive Summary

3. Acute Kidney Injury Overview

4. Acute Kidney Injury- Analytical Perspective In-depth Commercial Assessment

5. Acute Kidney Injury Pipeline Therapeutics

6. Acute Kidney Injury Late Stage Products (Phase II/III)

7. Acute Kidney Injury Mid Stage Products (Phase II)

8. Acute Kidney Injury Early Stage Products (Phase I)

9. Acute Kidney Injury Preclinical Stage Products

10. Acute Kidney Injury Therapeutics Assessment

11. Acute Kidney Injury Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Kidney Injury Key Companies

14. Acute Kidney Injury Key Products

15. Acute Kidney Injury Unmet Needs

16 . Acute Kidney Injury Market Drivers and Barriers

17. Acute Kidney Injury Future Perspectives and Conclusion

18. Acute Kidney Injury Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exploring the Landscape of Acute Kidney Injury Pipeline Drugs 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, & ROA Unveiled by DelveInsight | Atox Bio, AM Pharma Holding, QuarK

Chronic Refractory Cough Pipeline Drugs Update (2023) – FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Administration Routes by DelveInsight | Focus on Genentech and Trevi

“Chronic Refractory Cough Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Refractory Cough pipeline constitutes key companies continuously working towards developing Chronic Refractory Cough treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Chronic Refractory Cough Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Refractory Cough Market.

The Chronic Refractory Cough Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Refractory Cough Pipeline Report:

Companies across the globe are diligently working toward developing novel Chronic Refractory Cough treatment therapies with a considerable amount of success over the years.
Chronic Refractory Cough companies working in the treatment market are Nocion Therapeutics, Genentech, Inc., Trevi Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, Bellus Health Inc, Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., and others, are developing therapies for the Chronic Refractory Cough treatment

Emerging Chronic Refractory Cough therapies in the different phases of clinical trials are- NOC-100, GDC-6599, Haduvio, HRS-2261, BLU-5937, MK-7264 (gefapixant), Orvepitant Maleate, Camlipixant (BLU-5937), AX-8, ADX-629, GDC-6599, and others are expected to have a significant impact on the Chronic Refractory Cough market in the coming years.
In June 2023, Bellus Health Inc. and GSK plc declared Bellus has been fully acquired by GSK. Camlipixant, a potentially best-in-class and highly selective P2X3 antagonist that is presently in phase III development for the first-line treatment of adult patients with refractory chronic cough, is part of the Bellus purchase.
In January 2023, A Phase III, 24-week, randomized, double-blind, placebo-controlled, parallel-arm effectiveness and safety trial was started by Bellus Health Inc. with an open-label extension of BLU-5937 for adult participants with refractory chronic cough, including chronic cough that is not explained. The experiment is expected to conclude with 675 participants by July 2025.
In October 2022, A 52-week Phase III randomized, double-blind, placebo-controlled, parallel-arm effectiveness and safety trial was started by Bellus Health Inc. with an open-label extension of blu-5937 for adult participants with refractory chronic cough, including chronic cough without apparent cause.

Chronic Refractory Cough Overview

A cough that lasts longer than eight weeks is referred to as chronic, and many individuals with chronic refractory cough have coughs that last considerably longer. Furthermore, the illness is known as chronic refractory cough when the reason of the persistent cough cannot be found or the cough continues even after receiving the best care possible for any related conditions.

Get a Free Sample PDF Report to know more about Chronic Refractory Cough Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/chronic-refractory-cough-pipeline-insight

Emerging Chronic Refractory Cough Drugs Under Different Phases of Clinical Development Include:

NOC-100: Nocion Therapeutics
GDC-6599: Genentech, Inc.
Haduvio: Trevi Therapeutics
HRS-2261: Guangdong Hengrui Pharmaceutical Co., Ltd
BLU-5937: Bellus Health Inc
MK-7264 (gefapixant): Merck & Co/Kyorin Pharmaceuticals
Orvepitant Maleate: NeRRe Therapeutics
Camlipixant (BLU-5937): Bellus Health/GSK
AX-8: Axalbion
ADX-629: Aldeyra Therapeutics
GDC-6599: Genentech, Inc.

Chronic Refractory Cough Pipeline Therapeutics Assessment

Chronic Refractory Cough Assessment by Product Type
Chronic Refractory Cough By Stage and Product Type
Chronic Refractory Cough Assessment by Route of Administration
Chronic Refractory Cough By Stage and Route of Administration
Chronic Refractory Cough Assessment by Molecule Type
Chronic Refractory Cough by Stage and Molecule Type

DelveInsight’s Chronic Refractory Cough Report covers around products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Chronic Refractory Cough product details are provided in the report. Download the Chronic Refractory Cough pipeline report to learn more about the emerging Chronic Refractory Cough therapies

Some of the key companies in the Chronic Refractory Cough Therapeutics Market include:

Key companies developing therapies for Chronic Refractory Cough are – Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, Shionogi, Axalbion, Aldeyra Therapeutics and others

Chronic Refractory Cough Pipeline Analysis:

The Chronic Refractory Cough pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Refractory Cough with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Refractory Cough Treatment.
Chronic Refractory Cough key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chronic Refractory Cough Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Refractory Cough market.

Download Sample PDF Report to know more about Chronic Refractory Cough drugs and therapies

Chronic Refractory Cough Pipeline Market Drivers

Increasing Prevalence of cough, growing demand for treatment for Chronic Refractory Cough are some of the important factors that are fueling the Chronic Refractory Cough Market.

Chronic Refractory Cough Pipeline Market Barriers

However, lack of awareness, lack of availability of specific biomarkers that are useful for accurate and timely diagnosis and other factors are creating obstacles in the Chronic Refractory Cough Market growth.

Scope of Chronic Refractory Cough Pipeline Drug Insight

Coverage: Global
Key Chronic Refractory Cough Companies: Nocion Therapeutics, Genentech, Inc., Trevi Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, Bellus Health Inc, Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., and others
Key Chronic Refractory Cough Therapies: NOC-100, GDC-6599, Haduvio, HRS-2261, BLU-5937, MK-7264 (gefapixant), Orvepitant Maleate, Camlipixant (BLU-5937), AX-8, ADX-629, GDC-6599, and others
Chronic Refractory Cough Therapeutic Assessment: Chronic Refractory Cough current marketed and Chronic Refractory Cough emerging therapies
Chronic Refractory Cough Market Dynamics: Chronic Refractory Cough market drivers and Chronic Refractory Cough market barriers

Request for Sample PDF Report for Chronic Refractory Cough Pipeline Assessment and clinical trials

Table of Contents

1. Chronic Refractory Cough Report Introduction

2. Chronic Refractory Cough Executive Summary

3. Chronic Refractory Cough Overview

4. Chronic Refractory Cough- Analytical Perspective In-depth Commercial Assessment

5. Chronic Refractory Cough Pipeline Therapeutics

6. Chronic Refractory Cough Late Stage Products (Phase II/III)

7. Chronic Refractory Cough Mid Stage Products (Phase II)

8. Chronic Refractory Cough Early Stage Products (Phase I)

9. Chronic Refractory Cough Preclinical Stage Products

10. Chronic Refractory Cough Therapeutics Assessment

11. Chronic Refractory Cough Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Refractory Cough Key Companies

14. Chronic Refractory Cough Key Products

15. Chronic Refractory Cough Unmet Needs

16 . Chronic Refractory Cough Market Drivers and Barriers

17. Chronic Refractory Cough Future Perspectives and Conclusion

18. Chronic Refractory Cough Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Refractory Cough Pipeline Drugs Update (2023) – FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Administration Routes by DelveInsight | Focus on Genentech and Trevi

Exploring Acute Myeloid Leukemia Pipeline and Clinical Trials 2023: FDA Approvals, Therapeutic Advances, Companies Analyzed by DelveInsight | SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma

“Acute Myeloid Leukemia Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acute Myeloid Leukemia pipeline constitutes 260+ key companies continuously working towards developing 260+ Acute Myeloid Leukemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acute Myeloid Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Acute Myeloid Leukemia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Myeloid Leukemia Market.

Some of the key takeaways from the Acute Myeloid Leukemia Pipeline Report:

Companies across the globe are diligently working toward developing novel Acute Myeloid Leukemia treatment therapies with a considerable amount of success over the years.
Acute Myeloid Leukemia companies working in the treatment market are SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma Co., Ltd., Syros Pharmaceuticals, TC Biopharm, Stemline Therapeutics, Orca Bio, Gilead Sciences, GlycoMimetics, CicloMed LLC, Jazz Pharmaceuticals, Minneamrita Therapeutics LLC, Syndax Pharmaceuticals, Astex Pharmaceuticals, Inc., Karyopharm Therapeutics Inc, Sanofi, and others, are developing therapies for the Acute Myeloid Leukemia treatment

Emerging Acute Myeloid Leukemia therapies in the different phases of clinical trials are- GNC 035, JSP 191, ONC201, AK117, Tamibarotene, TCB008, Elzonris, Orca T, Magrolimab+ azacitidine, Uproleselan, Fosciclopirox + Cytarabine, CPX351, Minnelide, SNDX-5613, ASTX727, KPT-9274, SAR445419, and others are expected to have a significant impact on the Acute Myeloid Leukemia market in the coming years.
In January 2023, Preclinical findings demonstrating the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123 was published in Nature Biotechnology, according to a statement from Innate Pharma SA.
In January 2023, According to a news statement from Jubilant Therapeutics, the FDA designated JBI-802 as an orphan medication for patients with acute myeloid leukemia (AML) and small cell lung cancer (SCLC).
In January 2022, Astex Pharmaceuticals, Inc. declared that the oral fixed-dose combination of decitabine and cedazuridine (ASTX727) for the treatment of acute myeloid leukemia (AML) has been given orphan-drug designation (ODD) by the European Commission (EC).
In August 2022, Announcing that it will keep revising its estimate for the mid-2023 survival events trigger for its pivotal Phase 3 trial assessing uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML), GlycoMimetics said.

Acute Myeloid Leukemia Overview

About 80 percent of occurrences of leukemia in adults are acute myeloid leukemia (AML), making it the most prevalent kind in this population. The condition is typified by the clonal proliferation of immature “blast cells” in the bone marrow and peripheral circulation, leading to inefficient erythropoiesis and bone marrow failure.

Get a Free Sample PDF Report to know more about Acute Myeloid Leukemia Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight

Emerging Acute Myeloid Leukemia Drugs Under Different Phases of Clinical Development Include:

GNC 035: SystImmune
JSP 191: Jasper Therapeutics
ONC201: Chimerix
AK117: Akeso Biopharma Co., Ltd.
Tamibarotene: Syros Pharmaceuticals
TCB008: TC Biopharm
Elzonris: Stemline Therapeutics
Orca T: Orca Bio
Magrolimab+ azacitidine: Gilead Sciences
Uproleselan: GlycoMimetics
Fosciclopirox + Cytarabine: CicloMed LLC
CPX351: Jazz Pharmaceuticals
Minnelide: Minneamrita Therapeutics LLC
SNDX-5613: Syndax Pharmaceuticals
ASTX727: Astex Pharmaceuticals, Inc.
KPT-9274: Karyopharm Therapeutics Inc
SAR445419: Sanofi

Acute Myeloid Leukemia Route of Administration

Acute Myeloid Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Intravenous
Subcutaneous

Acute Myeloid Leukemia Molecule Type

Acute Myeloid Leukemia Products have been categorized under various Molecule types, such as

Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy

Acute Myeloid Leukemia Pipeline Therapeutics Assessment

Acute Myeloid Leukemia Assessment by Product Type
Acute Myeloid Leukemia By Stage and Product Type
Acute Myeloid Leukemia Assessment by Route of Administration
Acute Myeloid Leukemia By Stage and Route of Administration
Acute Myeloid Leukemia Assessment by Molecule Type
Acute Myeloid Leukemia by Stage and Molecule Type

DelveInsight’s Acute Myeloid Leukemia Report covers around 260+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Acute Myeloid Leukemia product details are provided in the report. Download the Acute Myeloid Leukemia pipeline report to learn more about the emerging Acute Myeloid Leukemia therapies

Some of the key companies in the Acute Myeloid Leukemia Therapeutics Market include:

Key companies developing therapies for Acute Myeloid Leukemia are – CicloMed LLC, Jazz Pharmaceuticals, Minneamrita Therapeutics LLC, Syndax Pharmaceuticals, Astex Pharmaceuticals, Inc., Karyopharm Therapeutics Inc, Sanofi, Polaris Group, Bio-Path Holdings, Inc., Chordia Therapeutics, Inc., Theradex, BioTheryX, Inc., Precigen, Inc, Eli Lilly and Company, Bayer, Takeda, Meryx, Inc., 2seventy bio, JW Pharmaceutical, Telios Pharma, and others.

Acute Myeloid Leukemia Pipeline Analysis:

The Acute Myeloid Leukemia pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Acute Myeloid Leukemia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Myeloid Leukemia Treatment.
Acute Myeloid Leukemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Myeloid Leukemia market.

Download Sample PDF Report to know more about Acute Myeloid Leukemia drugs and therapies

Acute Myeloid Leukemia Pipeline Market Drivers

Rising incidence of Acute Myeloid Leukemia, advancements in pharmacology and molecular biology to promote drug development, rising geriatric population are some of the important factors that are fueling the Acute Myeloid Leukemia Market.

Acute Myeloid Leukemia Pipeline Market Barriers

However, high cost associated with the management of AML, side effects associated with the AML treatment and other factors are creating obstacles in the Acute Myeloid Leukemia Market growth.

Scope of Acute Myeloid Leukemia Pipeline Drug Insight

Coverage: Global
Key Acute Myeloid Leukemia Companies: SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma Co., Ltd., Syros Pharmaceuticals, TC Biopharm, Stemline Therapeutics, Orca Bio, Gilead Sciences, GlycoMimetics, CicloMed LLC, Jazz Pharmaceuticals, Minneamrita Therapeutics LLC, Syndax Pharmaceuticals, Astex Pharmaceuticals, Inc., Karyopharm Therapeutics Inc, Sanofi, and others
Key Acute Myeloid Leukemia Therapies: GNC 035, JSP 191, ONC201, AK117, Tamibarotene, TCB008, Elzonris, Orca T, Magrolimab+ azacitidine, Uproleselan, Fosciclopirox + Cytarabine, CPX351, Minnelide, SNDX-5613, ASTX727, KPT-9274, SAR445419, and others
Acute Myeloid Leukemia Therapeutic Assessment: Acute Myeloid Leukemia current marketed and Acute Myeloid Leukemia emerging therapies
Acute Myeloid Leukemia Market Dynamics: Acute Myeloid Leukemia market drivers and Acute Myeloid Leukemia market barriers

Request for Sample PDF Report for Acute Myeloid Leukemia Pipeline Assessment and clinical trials

Table of Contents

1. Acute Myeloid Leukemia Report Introduction

2. Acute Myeloid Leukemia Executive Summary

3. Acute Myeloid Leukemia Overview

4. Acute Myeloid Leukemia- Analytical Perspective In-depth Commercial Assessment

5. Acute Myeloid Leukemia Pipeline Therapeutics

6. Acute Myeloid Leukemia Late Stage Products (Phase II/III)

7. Acute Myeloid Leukemia Mid Stage Products (Phase II)

8. Acute Myeloid Leukemia Early Stage Products (Phase I)

9. Acute Myeloid Leukemia Preclinical Stage Products

10. Acute Myeloid Leukemia Therapeutics Assessment

11. Acute Myeloid Leukemia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Myeloid Leukemia Key Companies

14. Acute Myeloid Leukemia Key Products

15. Acute Myeloid Leukemia Unmet Needs

16 . Acute Myeloid Leukemia Market Drivers and Barriers

17. Acute Myeloid Leukemia Future Perspectives and Conclusion

18. Acute Myeloid Leukemia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exploring Acute Myeloid Leukemia Pipeline and Clinical Trials 2023: FDA Approvals, Therapeutic Advances, Companies Analyzed by DelveInsight | SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma

Pancreatic Ductal Adenocarcinoma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Alligator Bioscience, Cardiff Oncology, Novartis, and others.

DelveInsight’s, “Pancreatic Ductal Adenocarcinoma Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the Pancreatic Ductal Adenocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Ductal Adenocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report

DelveInsight’s Pancreatic Ductal Adenocarcinoma Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma.
The leading companies working in the Pancreatic Ductal Adenocarcinoma Market include Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others are evaluating new drugs for pancreatic ductal adenocarcinoma to improve the treatment landscape.
Promising Pancreatic Ductal Adenocarcinoma Pipeline therapies include Mitazalimab, Onvansertib, NIS793, KN046, CAN04, NLM-001, Immuncell-LC, OSE2101, YH003, SBP-101, JPI-547, ELI-002, CEND-1, siG12D-LODER, AMP945, BMS-813160, CAN04, RMC-6236, AB122, GEN1042, DCC-3116, NGM707, AMT-151, SGN-CD228A, PEN-866, TJ033721, INCB106385, ZB131, BR55, CEND-1, BAY2287411, SD-101, JAB-21822, CM24, and others.
December 2023: Genentech Inc. announced a study of Phase 2 clinical trials for Autogene cevumeran and Atezolizumab. The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
December 2023: Georgetown University announced a study of Phase 2 clinical trials for Daratumumab and KRAS Vaccine. The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death protein 1) mAb (nivolumab) in patients with advanced non-small cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma (PDAC).
November 2023: Agenus Inc. announced a study of Phase 2 clinical trials for Botensilimab and Gemcitabine. The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive chemotherapy while a second group of participants will receive botensilimab and chemotherapy.

Request a sample and discover the recent advances in Pancreatic Ductal Adenocarcinoma Treatment Drugs @ Pancreatic Ductal Adenocarcinoma Pipeline Report

In the Pancreatic Ductal Adenocarcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Ductal Adenocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Pancreatic Ductal Adenocarcinoma Overview

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, with an average 5-year survival rate of less than 10%. Unfortunately, the majority of patients have unresectable, locally advanced, or metastatic disease at the time of diagnosis. PDAC development is associated with a poor prognosis due to its complicated and multifactorial nature.

Find out more about Pancreatic Ductal Adenocarcinoma Treatment Landscape @ Drugs for Pancreatic Ductal Adenocarcinoma Treatment

Pancreatic Ductal Adenocarcinoma Emerging Drugs Profile

Onvansertib: Cardiff Oncology
Nadunolimab: Cantargia
Zimberelimab: Arcus Biosciences

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies Pancreatic Ductal Adenocarcinoma. The Pancreatic Ductal Adenocarcinoma companies which have their Pancreatic Ductal Adenocarcinoma drug candidates in the most advanced stage, i.e phase III include XOMA.

DelveInsight’s Pancreatic Ductal Adenocarcinoma pipeline report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as

Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy

Learn more about the emerging Pancreatic Ductal Adenocarcinoma Pipeline Therapies @ Pancreatic Ductal Adenocarcinoma Clinical Trials Assessment

Scope of the Pancreatic Ductal Adenocarcinoma Pipeline Report

Coverage- Global
Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Pancreatic Ductal Adenocarcinoma Companies- Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others.
Pancreatic Ductal Adenocarcinoma Pipeline Therapies- Mitazalimab, Onvansertib, NIS793, KN046, CAN04, NLM-001, Immuncell-LC, OSE2101, YH003, SBP-101, JPI-547, ELI-002, CEND-1, siG12D-LODER, AMP945, BMS-813160, CAN04, RMC-6236, AB122, GEN1042, DCC-3116, NGM707, AMT-151, SGN-CD228A, PEN-866, TJ033721, INCB106385, ZB131, BR55, CEND-1, BAY2287411, SD-101, JAB-21822, CM24, and others.

Dive deep into rich insights for new drugs for Pancreatic Ductal Adenocarcinoma treatment, Visit @ Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Pancreatic Ductal Adenocarcinoma Executive Summary
Pancreatic Ductal Adenocarcinoma: Overview
Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics
Pancreatic Ductal Adenocarcinoma Therapeutic Assessment
Pancreatic Ductal Adenocarcinoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
NIS 793: XOMA
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
CEND 1: Cend Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
DCC-3116: Deciphera Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
RMC-6236: REVOLUTION Medicines
Drug profiles in the detailed report…..
Inactive Products
Pancreatic Ductal Adenocarcinoma Key Companies
Pancreatic Ductal Adenocarcinoma Key Products
Pancreatic Ductal Adenocarcinoma- Unmet Needs
Pancreatic Ductal Adenocarcinoma- Market Drivers and Barriers
Pancreatic Ductal Adenocarcinoma- Future Perspectives and Conclusion
Pancreatic Ductal Adenocarcinoma Analyst Views
Pancreatic Ductal Adenocarcinoma Key Companies
Appendix

For further information on the Pancreatic Ductal Adenocarcinoma pipeline therapeutics, reach out @ Pancreatic Ductal Adenocarcinoma Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pancreatic Ductal Adenocarcinoma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Alligator Bioscience, Cardiff Oncology, Novartis, and others.